Sugi Predict

Sugi Predict / Compounds / SCHEMBL24251635

SCHEMBL24251635

SCHEMBL24251635

O=C(CN1CCN(CC(=O)OCc2ccccc2)CCN(CC(=O)OCc2ccccc2)CCN(CC(=O)OCc2ccccc2)CC1)OCc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.59
▸ L3MBTL1 Q9Y468 2/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ KMT2A Q03164 3/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ POLB P06746 1/20 0.55
▸ CYP2C19 P33261 2/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ SLC6A3 Q01959 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ PPARG P37231 1/20 0.49
▸ PPARA Q07869 1/20 0.49
▸ NOTUM Q6P988 1/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25419509 0.95 ALDH1A1 (0.55) ALDH1A1L3MBTL1MAPK1SMN1; SMN2KMT2A
SCHEMBL15776693 0.95 ALDH1A1 (0.55) ALDH1A1L3MBTL1MAPK1SMN1; SMN2KMT2A
SCHEMBL5548988 0.95 ALDH1A1 (0.55) ALDH1A1L3MBTL1MAPK1SMN1; SMN2KMT2A
SCHEMBL25001507 0.93 ALDH1A1 (0.64) ALDH1A1L3MBTL1MAPK1SMN1; SMN2KMT2A
SCHEMBL3569051 0.93 ALDH1A1 (0.68) ALDH1A1L3MBTL1MAPK1SMN1; SMN2KMT2A
SCHEMBL24027122 0.92 ALDH1A1 (0.52) ALDH1A1L3MBTL1MAPK1SMN1; SMN2KMT2A
SCHEMBL1127697 0.92 PPARG (0.58) ALDH1A1L3MBTL1MAPK1SMN1; SMN2KMT2A
SCHEMBL15985781 0.92 ALDH1A1 (0.53) ALDH1A1L3MBTL1MAPK1SMN1; SMN2KMT2A
SCHEMBL17921387 0.92 ALDH1A1 (0.53) ALDH1A1L3MBTL1MAPK1SMN1; SMN2KMT2A
SCHEMBL14446963 0.92 ALDH1A1 (0.52) ALDH1A1L3MBTL1MAPK1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220098329-A1 HETERODIMERIC TETRAVALENCY AND SPECIFICITY ANTIBODY COMPOSITIONS AND USES THEREOF MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2022-03-31 — — US claimed
CN-122075404-A Liquid formulations and methods for inhibiting pentetic acid degradation — 2026-05-26 — — CN disclosed
US-12533428-B2 Multimodal fluorine-CY3/5/7-DOTA-hapten compositions, diagnostics, fluorescence guided surgery and radioimmunotherapy MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2026-01-27 — — US disclosed
US-20250295794-A1 MODULAR SELF ASSEMBLY DISASSEMBLY (SADA) TECHNOLOGIES MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2025-09-25 — — US disclosed
US-12343401-B2 Modular self assembly disassembly (SADA) technologies MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2025-07-01 — — US disclosed
WO-2025064419-A1 GPA33 ANTIBODY COMPOSITIONS AND USES THEREOF MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2025-03-27 — — WO disclosed
CN-117794568-A anti-GPA 33 multispecific antibodies and uses thereof 纪念斯隆凯特琳癌症中心 2024-03-29 — — CN disclosed
US-20240026037-A1 ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2024-01-25 — — US disclosed
US-20230398239-A1 Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies WISCONSIN ALUMNI RESEARCH FOUNDATION 2023-12-14 — — US disclosed
EP-4247426-A2 ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF Memorial Sloan Kettering Cancer Center (US) 2023-09-27 — — EP disclosed
US-20230158162-A1 MODULAR SELF ASSEMBLY DISASSEMBLY (SADA) TECHNOLOGIES MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2023-05-25 — — US disclosed
US-20230095707-A1 MULTIMODAL FLUORINE-CY3/5/7-DOTA-HAPTEN COMPOSITIONS, DIAGNOSTICS, FLUORESCENCE GUIDED SURGERY AND RADIOIMMUNOTHERAPY MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2023-03-30 — — US disclosed
US-11583588-B2 Modular self assembly disassembly (SADA) technologies MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2023-02-21 — — US disclosed
WO-2022108976-A2 ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2022-05-27 — — WO disclosed
US-20220098329-A1 HETERODIMERIC TETRAVALENCY AND SPECIFICITY ANTIBODY COMPOSITIONS AND USES THEREOF MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2022-03-31 — — US disclosed
US-20220048935-A1 Radioactive Phospholipid Metal Chelates for Cancer Imaging and Therapy WISCONSIN ALUMNI RESEARCH FOUNDATION 2022-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230398239-A1 Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies CD274, CD47, PDCD1 ALDH1A1 3521/4885L3MBTL1 50/4885MAPK1 985/4885
US-12533428-B2 Multimodal fluorine-CY3/5/7-DOTA-hapten compositions, diagnostics, fluorescence guided surgery and radioimmunotherapy CA13, CA12, CA14 ALDH1A1 2915/4885L3MBTL1 1378/4885MAPK1 1240/4885
US-20230095707-A1 MULTIMODAL FLUORINE-CY3/5/7-DOTA-HAPTEN COMPOSITIONS, DIAGNOSTICS, FLUORESCENCE GUIDED SURGERY AND RADIOIMMUNOTHERAPY CD68, FUCA1, CD58 ALDH1A1 2833/4885L3MBTL1 894/4885MAPK1 3980/4885
US-20220048935-A1 Radioactive Phospholipid Metal Chelates for Cancer Imaging and Therapy PHOSPHO1, H1-3, H1-0 ALDH1A1 2003/4885L3MBTL1 813/4885MAPK1 3969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.